Your browser doesn't support javascript.
loading
Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease.
Chen, Liang; Lu, Zhanjun; Kang, Dengfeng; Feng, Zhongsheng; Li, Gengfeng; Sun, Mingming; Liu, Zhanju; Wu, Wei; Fang, Leilei.
Afiliação
  • Chen L; Center for Inflammatory Bowel Disease Research, The Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Lu Z; Department of Gastroenterology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Kang D; Center for Inflammatory Bowel Disease Research, The Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Feng Z; Center for Inflammatory Bowel Disease Research, The Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Li G; Center for Inflammatory Bowel Disease Research, The Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Sun M; Center for Inflammatory Bowel Disease Research, The Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Liu Z; Center for Inflammatory Bowel Disease Research, The Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Wu W; Center for Inflammatory Bowel Disease Research, The Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Fang L; Center for Inflammatory Bowel Disease Research, The Shanghai 10th People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Front Pharmacol ; 13: 913720, 2022.
Article em En | MEDLINE | ID: mdl-36034848

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China